Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Profit After Tax (2023 - 2025)

Monte Rosa Therapeutics' Profit After Tax history spans 3 years, with the latest figure at -$46.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 443.15% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached -$38.6 million, up 46.91%, while the annual FY2025 figure was -$38.6 million, 46.91% up from the prior year.
  • Profit After Tax reached -$46.1 million in Q4 2025 per GLUE's latest filing, down from -$27.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $46.9 million in Q1 2025 to a low of -$46.1 million in Q4 2025.
  • Average Profit After Tax over 3 years is -$20.6 million, with a median of -$31.1 million recorded in 2024.
  • The largest YoY upside for Profit After Tax was 246.66% in 2025 against a maximum downside of 443.15% in 2025.
  • A 3-year view of Profit After Tax shows it stood at -$33.3 million in 2023, then skyrocketed by 140.35% to $13.4 million in 2024, then plummeted by 443.15% to -$46.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Profit After Tax are -$46.1 million (Q4 2025), -$27.1 million (Q3 2025), and -$12.3 million (Q2 2025).